Biofilms and Antifungal Susceptibility Testing

Simitsopoulou, Maria; Chatzimoschou, Athanasios; Roilides, Emmanuel

doi:10.1007/978-1-4939-3052-4_14

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-caboxanilide) reduction assay was used to assess the biofilm-forming capacity of each isolate as previously described with some modifications [ 19 , 20 ].…”

Section: Methodsmentioning

confidence: 99%

First report of Candida auris in Guangdong, China: clinical and microbiological characteristics of 7 episodes of candidemia

Peng,

Liu,

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

Candida auris is an emerging multidrug-resistant fungal pathogen worldwide. To date, it has not been reported in Guangdong, China. For the first time, we reported 7 cases of C. auris candidemia from two hospitals in Guangdong. The clinical and microbiological characteristics of these cases were investigated carefully. Two geographic clades, i.e. III and I, were found popular in different hospitals by whole genome sequencing analyses. All C. auris isolates from bloodstream were resistant to fluconazole, 5 of which belonged to Clade III harbouring VF125AL mutation in the ERG11 gene. The isolates with Clade I presented Y132F mutation in the ERG11 gene as well as resistance to amphotericin B. All isolates exhibited strong biofilm-forming capacity and non-aggregative phenotype. The mean time from admission to onset of C. auris candidemia was 39.4 days (range: 12 - 80 days). Despite performing appropriate therapeutic regimen, 42.9% (3/7) of patients experienced occurrences of C. auris candidemia and colonization after the first positive bloodstream. C. auris colonization was still observed after the first C. auris candidemia for 81 days in some patient. Microbiologic eradication from bloodstream was achieved in 85.7% (6/7) of patients at discharge. In conclusion, this study offers a crucial insight into unravelling the multiple origins of C. auris in Guangdong, highlighting great challenges in clinical prevention and control.

show abstract

Section: Methodsmentioning

confidence: 99%

First report of Candida auris in Guangdong, China: clinical and microbiological characteristics of 7 episodes of candidemia

Peng,

Liu,

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

Clinical impact of Candida spp. biofilm production in a cohort of patients with candidemia

et al. 2017

View full text Add to dashboard Cite

Persistent candidemia refers to the continued isolation of the same Candida species in the blood of a candidemic patient despite appropriate therapy. Despite the clinical importance of persistent candidemia, studies have superficially addressed the biological conditions behind this phenomenon. The aim of this study was to evaluate the correlation between the biofilm-forming ability by Candida bloodstream isolates and the persistence of infection. A total of 55 isolates of Candida were tested and characterized in two groups: (i) group I, which included seven patients with persistent candidemia, and (ii) group II, which included 18 patients with nonpersistent candidemia. Microorganisms were identified at the species level by sequencing the internal transcribed spacer (ITS) region of ribosomal DNA (rDNA). Biofilm quantification was evaluated by the crystal violet staining method and confocal scanning laser microscopy (CSLM). Molecular tests confirmed the identification of Candida albicans (92% group I and 94% group II) and Candida dubliniensis isolates (8% group I and 6% group II). All 55 isolates were able to form biofilms, but a higher biofilm mass was produced by C. albicans/C. dubliniensis strains cultured from the persistent group (P < .05). Our data suggest that Candida sp. biofilm production should be considered a relevant biologic variable in explaining patients who fail to clear a bloodstream infection despite adequate antifungal treatment with triazoles.

show abstract

New and old tools to evaluate new antimicrobial peptides

et al. 2018

View full text Add to dashboard Cite

The emergence of antimicrobial resistance due to the overuse of antimicrobials together with the existence of naturally untreatable infections well demonstrates the need for new instruments to fight microbes. Antimicrobial peptides (AMPs) are a promising family of molecules in this regard, because they abundantly occur in nature and the results of preliminary studies of their clinical potential have been encouraging. However, further progress will benefit from the standardization of research methods to assess the antimicrobial properties of AMPs. Here we review the diverse methods used to study the antimicrobial power of AMPs and recommend a pathway to explore new molecules. The use of new methodologies to quantitatively evaluate the physical effect on bacterial biofilms such as force spectroscopy and surface cell damage evaluation, constitute novel approaches to study new AMPs.

show abstract

Biofilms and Antifungal Susceptibility Testing

Cited by 3 publications

References 16 publications

First report of Candida auris in Guangdong, China: clinical and microbiological characteristics of 7 episodes of candidemia

First report of Candida auris in Guangdong, China: clinical and microbiological characteristics of 7 episodes of candidemia

Clinical impact of Candida spp. biofilm production in a cohort of patients with candidemia

New and old tools to evaluate new antimicrobial peptides

Contact Info

Product

Resources

About